Sign In
Buy HIMS
$27.51
+0 (+0%)
At Close: Jun 03, 2026
Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity
04:01am, Tuesday, 25'th Feb 2025
Hims & Hers stock fell ~19% post-Q4 earnings despite revenue beating expectations and EPS aligning with estimates, attributed to gross margin concerns and potential dependency on GLP-1 for future grow
Hims & Hers CFO, drone regulation: Asking for a Trend
10:49pm, Monday, 24'th Feb 2025
Josh Lipton takes a closer look at the top stories investors need to know after the closing bell on Asking for a Trend. Hims & Hers Health (HIMS) CFO Yemi Okupe breaks down the quarterly results as sh
Hims & Hers: Post Earnings Drop Is Very Welcomed
09:54pm, Monday, 24'th Feb 2025
Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted EBITD
Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics
07:31pm, Monday, 24'th Feb 2025
Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare wit
Markets Mostly Dip Red Late in Regular Trading
06:56pm, Monday, 24'th Feb 2025
After the closing bell, Zoom shares are -4% and HIMS are trading -17% lower on Q4 earnings results.
Hims & Hers Health, Inc. (HIMS) Lags Q4 Earnings Estimates
06:21pm, Monday, 24'th Feb 2025
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.01 per share a year ago.
Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins
06:05pm, Monday, 24'th Feb 2025
Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than-expected sales.
Hims & Hers shares tumble over concerns around weight-loss business
05:56pm, Monday, 24'th Feb 2025
The 'Fast Money' traders talk Hims & Hers shares falling despite beat as concerns around weight-loss business escalate.
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
10:55am, Monday, 24'th Feb 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Options Corner: HIMS Earnings Ahead
09:09am, Monday, 24'th Feb 2025
Hims & Hers Health (HIMS) had a volatile trading week ending with both a new 52-week high and a 18% drop. Rick Ducat examines the technical levels to track as investors prepare for the company's 4Q ea
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
01:45am, Monday, 24'th Feb 2025
Hims & Hers Health stock dropped 25% after the FDA announced the end of the semaglutide shortage, impacting Hims' weight loss services revenue. Hims plans to launch a generic version of liraglutide, b
Overlooked Stock: HIMS
04:34pm, Friday, 21'st Feb 2025
Hims & Hers Health (HIMS) sold off most of its massive rally today that it got over the last couple weeks. George Tsilis points out that the FDA no longer sees shortages of Novo Nordisk's (NVO) Ozempi
Why Hims & Hers Health Stock Is Plummeting Today
02:37pm, Friday, 21'st Feb 2025
Shares of Hims & Hers Health (HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m.
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
01:19pm, Friday, 21'st Feb 2025
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
12:56pm, Friday, 21'st Feb 2025
The FDA announced on Friday that the shortage of semaglutide injection products like Novo Nordisk's Ozempic and Wegovy has been resolved. The FDA said Friday that it will start taking action against
